Summary

Overview
Global molluscum contagiosum treatment market reached US$ XX billion in 2022 and is expected to reach US$ XX billion by 2030, growing with a CAGR of XX% during the forecast period 2023-2030.
Molluscum contagiosum is a poxvirus infection which is generally caused by a virus called the molluscum contagiosum. The infection in general causes a benign, skin-related illness with lesions that may develop anywhere on the body. It usually cures without scarring within 6-12 months, however, it can take up to 4 years as well depending upon the severity.
Treatment of the molluscum contagiosum includes physical removal, which includes therapies such as cryotherapy and laser therapy. Moreover, oral therapy includes cimetidine tablets. Furthermore, topical therapy includes the use of podophyllotoxin cream, tretinoin cream, cantharidin and imiquimod topical solution.
Recent trends and developments that can be seen in the treatment of molluscum contagiosum are topical drugs that are a new standardized preparation of topical cantharidin and topical nitric oxide. For instance, according to the National Library of Medicine, in Oct 2022, two experimental topical drugs were developed topical cantharidin, called VP-102 and other is the development of topical nitric oxide (NO)-releasing product containing berdazimer, known as SB206, represents a promising product that has been designed to overcome the limitations of current treatments.
The growth of this market is driven by factors such as a rise in product launches and approvals for the treatment of molluscum contagiosum, rise in clinical trials and studies, increasing R&D activities, advancements in treatment options and incorporation of novel formulation. However, high cost of clinical testing and molluscum contagiosum treatment are the major factors hampering the market's growth.
Dynamics
Rise in Product Launches and Approvals For The Treatment of Molluscum Contagiosum
The rise in product launches and approvals for the treatment of molluscum contagiosum is expected to drive the growth of the global molluscum contagiosum treatment market.
For instance, in July 2023, the FDA approved Ycanth (cantharidin) for the topical treatment of molluscum contagiosum in adult and pediatric patients with age group 2 years and older, making it the first treatment indicated for viral-borne skin disease. The pharmaceutical company developed this drug-device combination product with a controlled formulation of cantharidin (0.7% w/v). Thus, owing to the above factors it is expected to drive the market's growth.
Rise in Clinical trials and Studies
A rise in clinical trials and studies is expected to drive the global molluscum contagiosum (MC) treatment market. For instance in March 2022, the first-in-class topical therapy berdazimer gel 10.3% recently released its phase 3 data stating that the gel provided lesion count reduction by 4 weeks in patients with the molluscum contagiosum.
High Cost of Clinical Testing and Molluscum contagiosum treatment
The high cost of clinical testing and molluscum contagiosum treatment is expected to hamper the growth of the molluscum contagiosum (MC) treatment market. The cost of diagnosis typically including clinic visits and skin biopsy, which can cost around US $150 or more. Moreover, the costs of treatment for molluscum contagiosum cost can go up to US $1,500 for prescribed cream, depending upon the medication. Furthermore, the cost of tretinoin cream with the brand name retin-A costs around US $150 and generic podofilox solution costs around US $95.
Segment Analysis
The global molluscum contagiosum treatment market is segmented based on type, treatment type, end-user and region.
Cantharidin From The Treatment Type is Expected to Hold a Dominant Position in the Market over the Forecast Period.
Cantharidin from treatment type is the highest market share holder in the global molluscum contagiosum treatment market with a market share of arounf 45.7%. For instance, in July 2023, Verrica Pharmaceuticals received approval from the US Food and Drug Administration (FDA) for its YCANTH (cantharidin) topical solution to treat molluscum contagiosum. The FDA approval was based on positive data from two identical Phase III double-blind, multicentre and randomised clinical studies, CAMP-1 and CAMP-2.
Geographical Penetration
North America Holds the Largest Market Share in the global molluscum contagiosum treatment Market
North America dominates the global molluscum contagiosum treatment market with a market share of around 41.2% in 2022. For instance, in July 2022, Novan announced the publication of positive safety and efficacy data from its completed B-Simple 4 pivotal Phase 3 clinical study evaluating berdazimer gel, 10.3% for the treatment of molluscum. Results from the B-SIMPLE 4 clinical study strongly demonstrate the promise of berdazimer gel, 10.3% as a potential first and only prescription medication for molluscum. Thus, owing to the above factors North America is expected to hold the largest share in the market over the forecast period.
Competitive Landscape
The major global players in the market include CRYONiQ, Cryo Innovations, Powercab-Germany, BTL, Erchonia Corporation., Teva Pharmaceuticals USA, Inc., Aurobindo Pharma USA, GSK plc., Verrica Pharmaceuticals. and Leiters Health among others.
DMI Opinion
The market for Molluscum Contagiosum (MC) treatment is experiencing growth driven by several key factors. Firstly, the rise in product launches and approvals has significantly contributed to market expansion. FDA approvals for treatments like Ycanth (cantharidin) and VP-102 have paved the way for effective MC management. Secondly, there is an increase in clinical trials and studies, with promising results from Phase 3 trials of berdazimer gel and potassium hydroxide solutions. This has bolstered confidence in novel treatments.
Geographically, North America dominates the market, benefiting from positive study results and FDA approvals, such as Ycanth and berdazimer gel. However, the market faces challenges due to the high costs associated with clinical testing and MC treatment, potentially limiting access to care.
COVID-19 Impact Analysis
In response to the COVID-19 pandemic, there was a notable decrease in infectious diseases, including MC, likely due to changed behaviors and healthcare priorities. Nevertheless, the market for MC treatment remains dynamic, with new products and therapies offering hope for improved outcomes in the future.
By Type
• MCV-1
• MCV-2
• MCV-3
• MCV-4
By Treatment Type
• Physical Removal
o Cryotherapy
o Laser Therapy
• Oral Therapy
o Cimetidine
• Topical Therapy
o Podophyllotoxin Cream
o Iodine And Salicylic Acid
o Potassium Hydroxide
o Tretinoin
o Cantharidin
o Imiquimod
• Therapy for Immunocompromised Persons
By End-User
• Hospitals
• Skin Clinics
• Others
By Region
• North America
o U.S.
o Canada
o Mexico
• Europe
o Germany
o UK
o France
o Italy
o Spain
o Rest of Europe
• South America
o Brazil
o Argentina
o Rest of South America
• Asia-Pacific
o China
o India
o Japan
o Australia
o Rest of Asia-Pacific
• Middle East and Africa
Key Developments
• In July 2023, Verrica pharmaceuticals announced FDA approval of YCANTH topical solution as the first FDA-approved treatment of pediatric and adult patients with molluscum contagiosum. YCANTH is a drug-device combination product administered by a healthcare professional. Based on the results from Verrica’s clinical trials, the FDA found that YCANTH is safe and effective for patients as young as two years old.
• In March 2023, Berdazimer gel showed favorable outcomes in the molluscum contagiosum phase 3 study. A greater number of patients with molluscum contagiosum experienced complete clearance rates with berdazimer gel 10.3%. It is as per a study presented by the American Academy of Dermatology Annual Meeting. Browning presented results from the multicenter, randomized, double-blind, vehicle-controlled parallel trials from the B-SIMPLE phase 3 program evaluating the efficacy and safety of berdazimer gel 10.3% for treating molluscum contagiosum (MC).
Why Purchase the Report?
• To visualize the global molluscum contagiosum treatment market segmentation based on type, treatment type, end-user and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of molluscum contagiosum market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.
The global molluscum contagiosum treatment market report would provide approximately 61 tables, 60 figures and 221 Pages.
Target Audience 2024
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

ページTOPに戻る

Table of Contents

1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
3.1. Snippet by Type
3.2. Snippet by Treatment Type
3.3. Snippet by End-user
3.4. Snippet by Region
4. Dynamics
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. Rise in Product Launches and Approvals
4.1.1.2. Rise in Clinical Trials and Studies
4.1.2. Restraints
4.1.2.1. High Cost of Clinical Testing and Molluscum Contagiosum Treatment
4.1.3. Opportunity
4.1.3.1.1. Emerging markets
4.1.4. Impact Analysis
5. Industry Analysis
5.1. Porter's Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pipeline Analysis
5.4. SWOT Analysis
5.5. PESTEL Analysis
5.6. Pricing Analysis
5.7. Regulatory Analysis
6. COVID-19 Analysis
6.1. Analysis of COVID-19
6.1.1. Scenario Before COVID
6.1.2. Scenario During COVID
6.1.3. Scenario Post COVID
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During Pandemic
6.5. Manufacturers Strategic Initiatives
6.6. Conclusion
7. By Type
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
7.1.2. Market Attractiveness Index, By Type
7.2. MCV-1 *
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. MCV-2
7.4. MCV-3
7.5. MCV-4
8. By Treatment Type
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
8.1.2. Market Attractiveness Index, By Treatment Type
8.2. Physical Removal *
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.2.3. Cryotherapy
8.2.4. Laser Therapy
8.3. Oral Therapy
8.3.1. Cimetidine
8.4. Topical Therapy
8.4.1. Podophyllotoxin Cream
8.4.2. Iodine and Salicylic Acid
8.4.3. Potassium Hydroxide
8.4.4. Tretinoin
8.4.5. Cantharidin
8.4.6. Imiquimod
8.5. Therapy for Immunocompromised Persons
8.6. Others
9. By End-user
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
9.1.2. Market Attractiveness Index, By End-user
9.2. Hospitals
9.2.1. Introduction
9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Skin Clinics
9.4. Others
10. By Region
10.1. Introduction
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
10.1.2. Market Attractiveness Index, By Region
10.2. North America
10.2.1. Introduction
10.2.2. Key Region-Specific Dynamics
10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.2.6.1. U.S.
10.2.6.2. Canada
10.2.6.3. Mexico
10.3. Europe
10.3.1. Introduction
10.3.2. Key Region-Specific Dynamics
10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.3.6.1. Germany
10.3.6.2. UK
10.3.6.3. France
10.3.6.4. Italy
10.3.6.5. Spain
10.3.6.6. Rest of Europe
10.4. South America
10.4.1. Introduction
10.4.2. Key Region-Specific Dynamics
10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.4.6.1. Brazil
10.4.6.2. Argentina
10.4.6.3. Rest of South America
10.5. Asia-Pacific
10.5.1. Introduction
10.5.2. Key Region-Specific Dynamics
10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.5.6.1. China
10.5.6.2. India
10.5.6.3. Japan
10.5.6.4. Australia
10.5.6.5. Rest of Asia-Pacific
10.6. Middle East and Africa
10.6.1. Introduction
10.6.2. Key Region-Specific Dynamics
10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
10.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11. Competitive Landscape
11.1. Competitive Scenario
11.2. Market Positioning/Share Analysis
11.3. Mergers and Acquisitions Analysis
12. Company Profiles
12.1. CRYONiQ*
12.1.1. Company Overview
12.1.2. Product Portfolio and Description
12.1.3. Financial Overview
12.1.4. Key Developments
12.2. Cryo Innovations
12.3. Powercab-Germany
12.4. BTL
12.5. Erchonia Corporation.
12.6. Teva Pharmaceuticals USA, Inc.
12.7. Aurobindo Pharma USA
12.8. GSK plc.
12.9. Verrica Pharmaceuticals.
12.10. Leiters Health
LIST NOT EXHAUSTIVE
13. Appendix
13.1. About Us and Services
13.2. Contact Us